Author Search Results :: UTM Library Massive Scholar Tracking

1

Chimeric antigen receptor T‐cell therapy outcomes in T cell/histiocyte‐rich large B‐cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH stud... by Mariana Bastos‐Oreiro, Gloria Iacoboni, Víctor N. Garcés, Ana C. Caballero, Nuria Martínez, Javier Delgado, Aitana Balaguer, Mi Kwon, Sonia Gonzalez de Villambrosia, Rafael Hernani, Ana Jimenez‐Ubieto, Rebeca Bailen, Izaskun Zaberio, Alejandro Martín García‐Sancho, Pere Barba

Published 2025-02-01

Get full text

Article

2

$New therapies for relapsed or refractory aggressive B‐cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group$

New therapies for relapsed or refractory aggressive B‐cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group by Mariana Bastos‐Oreiro, Pau Abrisqueta, Antonio Gutierrez, Ana Jiménez Ubieto, Maria Poza, Paula Fernanez‐Caldas, María José LLacer, Sonia Gonzalez de Villambrosia, Raúl Córdoba, Alberto López, Elena Ceballos, Belen Navarro, Ana Muntañola, Eva Donato, Eva Diez‐Baeza, Lourdes Escoda, Hugo Luzardo, María José Peñarrubia, Daniel García Belmonte, Emilia Pardal, Claudia Lozada, Alejandro Martín García‐Sancho

Published 2024-04-01

Get full text

Article

3

Human immunodeficiency virus‐associated Lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up by Kai Hübel, Mark Bower, Igor Aurer, Mariana Bastos‐Oreiro, Caroline Besson, Uta Brunnberg, Chiara Cattaneo, Simon Collins, Kate Cwynarski, Alessia D. Pria, Marcus Hentrich, Christian Hoffmann, Marie J. Kersten, Silvia Montoto, Jose‐Tomas Navarro, Eric Oksenhendler, Alessandro Re, Josep‐Maria Ribera, Philipp Schommers, Bastian vonTresckow, Christian Buske, Martin Dreyling, Andy Davies, the EHA and ESMO Guidelines Committees

Published 2024-09-01

Get full text

Article

4

P1151: BENDAMUSTINE-CONTAINING REGIMENS CAN BE SAFELY USED AS BRIDGING IN LARGE B-CELL LYMPHOMA PATIENTS RECEIVING CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY by Gloria Ines Iacoboni Garcia-Calvo, Victor Navarro, Ana Africa Martin Lopez, Mariana Bastos Oreiro, Kai Rejeski, Katarzyna Aleksandra Jalowiec, Paula Amat, Juan Luis Reguera Ortega, Viktoria Blumenberg, Laura Gallur, María Herrero-García, Claire Roddie, Rebeca Bailen, Ana Benzaquen, Cecilia Carmen Carpio Segura, Lucía López Corral, Rafael Hernani, MI Kwon, Lourdes Martín-Martín, Marion Subklewe, Maeve O’reilly6, Pere Barba Suñol

Published 2023-08-01

Get full text

Article

5

P1401: IDENTIFICATION OF BIOMARKERS AND RISK FACTORS FOR IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS) IN CD19-DIRECTED CAR T-CELL THERAPY: A RETROSPECTIVE MACHINE... by Marina Gómez-Llobell, María Martínez García, Carlos Serra Smith, Daniel Gómez Costas, Gillen Oarbeascoa Royuela, Diego Carbonell, Javier Anguita Velasco, Ana María Pérez Corral, Marjorie Pion, Veronica Astrid Pérez-Fernández, Isabel Fernández García, Mariana Bastos Oreiro, Paula Fernández-Caldas González, Ignacio Gómez-Centurión, Ana Alarcón, Eva Catalá, Diego Conde, Jorge Gayoso, Pablo Olmos, Carolina Martínez Laperche, Jose García-Domínguez, Yolanda Fernández, Rebeca Bailen, MI Kwon

Published 2023-08-01

Get full text

Article

6

Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study by Isabel Regalado-Artamendi, Ana Jiménez-Ubieto, José Ángel Hernández-Rivas, Belén Navarro, Lucía Núñez, Concha Alaez, Raúl Córdoba, Francisco Javier Peñalver, Jimena Cannata, Pablo Estival, Keina Quiroz-Cervantes, Rosalía Riaza Grau, Alberto Velasco, Rafael Martos, Amalia Domingo-González, Laurentino Benito-Parra, Elvira Gómez-Sanz, Javier López-Jiménez, Arturo Matilla, María Regina Herraez, María José Penalva, Julio García-Suárez, José Luis Díez-Martín, Mariana Bastos-Oreiro

Published 2021-03-01

Get full text

Article

7

$Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups$

Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups by Mariana Bastos-Oreiro, Antonio Gutierrez, Juan Luís Reguera, Gloria Iacoboni, Lucía López-Corral, María José Terol, Valentín Ortíz-Maldonado, Jaime Sanz, Luisa Guerra-Dominguez, Rebeca Bailen, Alberto Mussetti, Pau Abrisqueta, Rafael Hernani, Hugo Luzardo, Juan-Manuel Sancho, Javier Delgado-Serrano, Antonio Salar, Carlos Grande, Leyre Bento, Sonia González de Villambrosía, Daniel García-Belmonte, Anna Sureda, Antonio Pérez-Martínez, Pere Barba, Mi Kwon, Alejandro Martín García-Sancho

Published 2022-07-01

Get full text

Article

8

$Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma$